NIH announces strategy for developing COVID-19 drugs, vaccines
April 21, 2020
Drug companies will collaborate across hundreds of clinical trials in effort to coordinate private coronavirus research, which has been marked by chaos thus far
The National Institutes of Health announced an initiative Friday to unify disparate efforts across the drug industry to respond to the coronavirus-related pandemic.
Pharmaceutical companies will collaborate across hundreds of COVID-19 clinical trials, the NIH says, by sharing “master protocols” on how those clinical trials will work.
“Collaboration is a critical ingredient for success and the FDA will continue to use every tool possible under our Coronavirus Treatment Acceleration Program to speed the development of safe and effective medical countermeasures,” said Food and Drug Administration Commissioner Stephen Hahn in a statement.
The coronavirus-related research race has been thus far marked by chaos as dozens of private companies and researchers compete for a cure, according to a recent news report.
Read the full article by Emily Kopp below.
Recent News
- Health Insurance Costs 2026: Steep Increases Ahead for Employers, Including Life Sciences
- Co-Diagnostics Forms New AI Business Unit and Expands Global Footprint with CoMira Diagnostics
- Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark
- Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East
- EDWARDS SAPIEN 3 TAVR DELIVERS PROVEN LONG-TERM BENEFITS AND VALVE PERFORMANCE, NEW DATA PRESENTED AT TCT 2025
- SUCCESSFUL PATIENT OUTCOMES DEMONSTRATED WITH EDWARDS’ SAPIEN M3 AND EVOQUE SYSTEMS, NEW DATA PRESENTED AT TCT 2025
